Bipolar Disorder

Neurology·MeSH: Bipolar Disorder

Prevalence

463.1 / 100K

Incidence

32.5 / 100K/yr

10 drugs in development·5 companies·16 clinical trials

Drug Pipeline by Phase

Approved(4)

Drug	Company
divalproex	Teva Pharmaceutical Industries Limited (TEVA)
lamotrigine	Teva Pharmaceutical Industries Limited (TEVA)
risperidone	NANOMIX CORP (BTHI)
uzedy	Teva Pharmaceutical Industries Limited (TEVA)

Phase 3(4)

Drug	Company
azetukalner	Xenon Pharmaceuticals Inc. (XENE)
Lamotrigine	BRISTOL MYERS SQUIBB CO (BMY)
Lithium	BRISTOL MYERS SQUIBB CO (BMY)
valproate	BRISTOL MYERS SQUIBB CO (BMY)

Phase 2/Phase 3(1)

Drug	Company
opakalim	Biohaven Ltd. (BHVN)

Phase 4(1)

Drug	Company
KarXT	BRISTOL MYERS SQUIBB CO (BMY)

BioSniper tracks 10 drugs in development for Bipolar Disorder across 5 companies.

There are 16 clinical trials targeting Bipolar Disorder tracked by BioSniper.

The estimated prevalence of Bipolar Disorder is approximately 463.1 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.